This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Link between effectiveness and cost data
The costing was performed retrospectively on the same sample of patients as that used in the effectiveness study.
Study sample
The appropriate sample size was calculated on the basis of the anticipated evaluability rate and expected clinical response rate. Of the 403 people enrolled, an overall sample of 268 clinically evaluable patients was identified. However, the final sample comprised 266 patients as one patient in each group was not economically evaluable. There were 136 patients (58 men) in the AZI group and 130 (61 men) in the CEF group. The mean age was 60.5 (+/-17.6) years in the AZI group and 60.1 (+/-17.7) years in the CEF group. Sixty-four patients in the CEF group also received ERY. It was not stated whether some patients refused to participate or were excluded from the initial study sample for any reason.
Study design
This was an open-label, randomised controlled trial, which was carried out in 36 centres. The patients were randomised 1:1 to the two study groups, but the method of randomisation was not described. No blind assessment of the outcome was performed. A first assessment was carried out 10 to 14 days post-therapy. The length of follow-up was 4 to 6 weeks after therapy. The loss to follow-up was not reported, but it appears that all patients were clinically evaluable at the end of the observation period.
Analysis of effectiveness
The authors did not state whether the analysis was carried out on an intention to treat basis. The primary health outcome used in the effectiveness study was the success rate (cure or improvement). Adverse events were also observed. The two groups were comparable at baseline in terms of the demographic and clinical characteristics.
Effectiveness results
At 10 to 14 days post-therapy, the success rate was 78% in the AZI group and 75% in the CEF group, (p=0.54).
At 4 to 6 weeks post-therapy, the success rate was 75% in the AZI group and 71% in the CEF group, (p=0.46).
Adverse events were observed in 11.8% of the patients in the AZI group and in 21.5% of those in the CEF group (7.6% among patients receiving only CEF and 35.9% among those who also received ERY).
Clinical conclusions
The effectiveness analysis showed that the two treatments were equally effective in terms of the success rate.
Modelling
A modelling approach was used to estimate the expected costs and benefits of the two alternative treatment strategies. The basis of the model was a decision tree. The branches of patients who were or were not receiving ERY were considered separately. Therefore, the final number of alternative options was three. The structure of the tree was reported in the paper. The model was deterministic and a sensitivity analysis was conducted to evaluate the impact of changing model parameters.
Measure of benefits used in the economic analysis
The summary benefit measure was the success rate. This was derived from the effectiveness study and then entered into the decision model. No discounting was applied. Adverse effects were not considered.
